Dynamic positron emission tomography with [ 18 Flfluorodeoxyglucose was used in six patients with Alzheimer's disease (AD) and seven healthy age-matched
control subjects to estimate the kinetic parameters K 1*' k2 *, and k3 * that describe glucose transport and phospho rylation. A high-resolution tomograph was used to ac quire brain uptake data in one tomographic plane, and a radial artery catheter connected to a plastic scintillator was used to acquire arterial input data. A nonlinear iter ative least-squares fitting procedure that included terms for the vascular fraction and time delay to the peripheral sampling site was used to fit a three-compartment model to the brain data. Regions studied included frontal, tem poral, occipital, and the entire cortex and subcortical white matter. The values obtained for the individual rate constants and regional CMR g lc (rCMR g lc: calculated us ing regional values of the rate constants) were higher than those reported previously. A significant (p < 0.05) de-Positron emission tomography (PET) has demon strated reduced regional CMRglc (rCMRg1J values in patients with Alzheimer ' s disease (AD). These findings predominate in temporal and parietal cor tical regions and have been reported by numerous laboratories (Benson et aI., 1983; Friedland et aI., 1983; Foster et aI., 1984; Duara et aI., 1986) . De spite this agreement, however, the mechanisms and significance of these metabolic alterations are poorly understood. crease was found in K I * in frontal and temporal cortex in the AD patients compared with the controls, with values of 0.157 and 0.161 mllg/min in frontal and temporal cor tex, respectively. of controls and 0.127 and 0. 126 mil g/min in frontal and temporal cortex of the AD patients. rCMR g lc was also significantly (p < 0.02) lower in the AD patients than controls in all cortical brain regions. Lower values of k3 * were found in all brain regions in the AD patients, although these were not statistically significant. These findings provide evidence of an in vivo abnormality of forward glucose transport in AD. This transport defect, however, is probably not the cause of the diminution in glucose metabolism that has been widely found in AD patients, since a diminution of this magnitude should not lower intracerebral glucose content enough to alter rCM R g lc. Key Words: Alzheimer's disease-Glucose metabo lism-Glucose transport-Positron emission tomogra phy.
Dynamic PET offers the ability to evaluate the mechanisms that may underlie changes in regional glucose metabolism. By acquiring PET measure ments of cerebral uptake of the glucose metabolic tracer [ J 8F]fluorodeoxyglucose (FDG) in conjunc tion with measurements of peripheral blood radio activity, we can utilize a three-compartment model as developed by Sokoloff et al. (1977) to estimate the parameters describing forward and reverse FDG transport (KJ* and k2*' respectively) and phosphorylation of FDG by the enzyme hexokinase (k3 *). This procedure allows the in vivo measure ment of different aspects of glucose metabolism that may be related to altered neuronal function. A previous report using dynamic PET to measure these rate constants in our laboratory did not find statistically significant differences in rate constants for glucose transport between patients with AD and healthy age-matched control subjects (Friedland et aI., 1989) . However, the development of higher resolution PET instrumentation and modifications of our experimental technique for input function sampling have since prompted us to repeat the study in a new group of patients.
MATERIALS AND METHODS

Patients
We studied six patients who met current research cri teria for probable AD (McKhann et aI., 1984) . All patients experienced progressive cognitive decline for at least I year, with primary disturbances of memory function. Pa tients did not take any medications, all were free of sig nificant medical illnesses, and all had laboratory and x ray computed tomography or magnetic resonance imag ing examinations to exclude other causes of dementia. All patients underwent a battery of cognitive tests designed to measure memory, language, visuospatial ability, and other aspects of intellectual functioning. Overall demen tia severity was assessed using the Mini-Mental Status Examination (Folstein et aI., 1975) . The mean age of the patients was 71.0 years (SD 5.6, range 63-76 years). The severity of dementia ranged from mild to severe, with Mini-Mental Status Examination scores ranging from 28 to 7 (SD 7.1, mean 17.2).
A group of seven healthy age-matched subjects served as controls. These subjects were recruited from the com munity at large or were the spouses of patients. No sub ject complained of memory loss or cognitive impairment and all were free of medical illnesses and were taking no medications. The mean age of control subjects was 69.4 years (SD 7.7, range 62-80 years).
PET imaging
All patients were studied with the Donner 600-crystal positron emission tomograph (PET 600), a single-slice in strument with a resolution of 2.6 mm in-plane full width at half-maximum (FWHM) and 6 mm axially. Characteris tics of the tomograph have been previously reported (Derenzo et aI., 1988) . Prior to imaging, a percutaneous catheter was inserted in the left radial artery. This cath eter was connected to a short Teflon tube (I-mm internal diameter, 0.3 mm thick), which was wrapped around a �-detecting plastic scintillator (Nuclear Enterprises NEI02A) and then connected to thicker tubing running through a peristaltic pump. The scintillator was lead shielded from other sources of radiation and optically connected to a photomultiplier tube for on-line determi nation of arterial radioactivity.
Immediately prior to injection of tracer, samples for blood glucose determination were obtained and the peri staltic pump was turned on. Blood was withdrawn at a rate of 10 mUmin for the first 5 min following tracer in jection and at 2 mllmin for the remaining 35 min of the study. An independent series of experiments determined the impulse response of the pump/detector system at dif ferent flow rates, and it was concluded that a flow rate of 10 mllmin caused negligible tracer dispersion through the apparatus.
Patients were placed in the supine position in the scan ner with the eyes and ears unoccluded. An external 20-mCi orbiting 68 Ga source was used to obtain a single transmission scan at �5 cm above and parallel to the inferior orbitomeatal line. This scan was used to correct emission data for attenuation and also to assist in posi tioning the patient.
Immediately following the injection of � 10 mCi of FDG, prepared as described previously (Ido et aI., 1978; Bida et aI., 1984) , arterial blood radioactivity was counted in the detector apparatus over I-s intervals for the first 2 min, followed by increasingly longer intervals to 40 min. Simultaneously, serial PET data were obtained according to the following schedule: 5-s files from 0 to I min, 10 s from I to 2 min, 30 s from 2 to 4 min, 60 s from 4 to 10 min, and 300 s from 10 to 40 min. At 40 min, blood col lection was stopped, but an additional 10 min of PET data were collected at the same tomographic level for use in image analysis. This 10 min of PET data was added to the previous 5-min scan and used to draw regions of interest (ROIs) only.
PET data analysis
The ROIs drawn on the final 15 min of PET data (from 35 to 50 min) were then used with the dynamic PET data obtained from 0 to 40 min to construct regional time activity curves. The method used (Huesman, 1984) al lowed evaluation of the statistical uncertainty of the data and utilized a ramp convolution filter without smoothing to limit spillover into or out of the ROI. Regions were drawn in frontal cortex, temporal cortex, occipital cortex, and frontal white matter of each hemisphere. In addition, a region called "entire cortex" was drawn to contain the entire cortical gray matter of each hemisphere. Anatomic boundaries of the regions were determined by reference to a standard computed tomography brain atlas (Matsui and Hirano, 1978) and were not contiguous. The sizes of the ROIs were on the order of I cm 3 in smaller brain regions such as white matter, 4 cm 3 in moderately sized regions such as frontal, temporal, and occipital cortex, and 13 cm 3 in the largest brain region, entire cortex. We did not analyze data from subcortical structures because the small sizes of these structures limited accurate PET statistics at early times after injection and because of the potential for greater partial volume errors due to the lim ited axial sampling of a single section.
The three-compartment model was then fit with the arterial time-activity curve from 0 to 40 min and the de rived brain time-activity curves using a nonlinear iterative weighted least-squares algorithim (Marquardt, 1963) . In addition to the model parameters describing FDG trans port and phosphorylation (K 1*' k2 *, and k3 *), we also fit for the fraction of the tracer in the vascular compartment (fJ and for the time offset (to) accounting for the differ ence in arrival of the tracer at the peripheral sampling scintillator and the ROI (Mazoyer et aI., 1986) . Because data were collected for 40 min, we did not fit for k4 * but used a value of k4 * = 0 in the model. The assumption of a different value for k4 * would be expected to produce only a scaling effect and not to affect the between-or within-subject coefficient of variation of the other model parameters, as has recently been shown by Dhawan et al. (1989) . The model included integration over the time in tervals of the PET data acquisition schedule, and the in put function was taken as linear interpolation between sampled blood points. The statistical uncertainties of the PET data were used as weighting factors in the least squares fit, but the noise in the blood data has not been accounted for. Further details concerning the parameters fv and to, the integral model, and the weighted least squares fitting procedure can be found in Mazoyer et al. (1986) . Glucose metabolic rates for each brain region were calculated using the formula rCMR g lc = r K] * k3 * I (k2 * + k3 *)]f CpILCJ, where Cp represents the plasma glu cose concentration and LC is the lumped constant value of 0.52 (Reivich et aI. , 1985) . The apparent volume of distribution of the tracer (Vd), given as K] */(k2 * + k3 *), was also calculated.
Statistics
We compared differences between AD and control groups for the variable rCMR g 1c using unpaired Student t tests with a Bonferroni correction to account for multiple comparisons. To assess differences between groups in the rate constants (K] * ,k2 * ,k3 *), we utilized multivariate analysis of variance with significance determined by the PilJai trace. Follow-up univariate t tests were examined only if the multivariate statistic was significant.
RESULTS
PET images from a control and an AD subject are shown in Fig. 1 . The I5-min images used for draw ing ROIs generally contained 1. 0-2. 0 x 10 6 true co incidence events.
PET data from a single brain region along with a sample input function and results of the model fit are shown in Fig. 2 . The uncertainties of the param eter estimates varied according to the size and lo cation of the regions analyzed, as well as the pa rameter estimated. Uncertainties were greater in smaller regions with fewer events and smaller in larger regions with more events. The smallest un- c AD certainties were for estimates of K, * in entire cor tex, ranging from 5 to 10% of the parameter's value. In frontal, temporal, and occipital cortex, these val ues were -10-15%. Uncertainties for estimates of k2 * and k3 * were generally in the range of 10-50% for gray matter regions. Uncertainties for estimates of rCMR g lc in gray matter were in the 5% range. The uncertainties for estimates ofiv were in the range of 20% for entire cortex and 30-50% for the smaller brain regions. Estimates of parameters in white matter were more uncertain, with uncertainties for K,* in the range of 20-40%, for k2* andiv 50-75%, and for k3* 75-150%. Even rCMR g lc in white matter frequently had uncertainties of 20-50%.
Values for to did not differ between AD and con trol subjects for any region. Values ranged between -9 and -12 s for most brain regions, with differ ences of -1-4 s for different regions within pa tients. The uncertainties of the estimates of to were generally between 1 and 3 s. Table 1 shows the average values for the rate constants and vascular fraction, along with the cal culated rCMR g lc and Vd, in the five different brain regions. Values are the means of left and right hemi spheres for all parameters. The coefficients of vari ation between subjects show a pattern similar to that seen in the uncertainties of the estimates; that is, the least variable parameters are K,* and rCMR g lc, while k2* ' iv, and k3* show more varia- tion. There was considerable variability of values in white matter as well. In general, values for K) *, k3 *, and rCMR g Ic were lower in the AD than in the con trol subjects, while values for k2 * were higher in the AD than the control subjects. Results of the multi variate analysis of variance, however, were signif icant only for the parameter K) *, which was signif icantly (p < 0.05) lower in the AD than the control groups in frontal and temporal cortex. Values of rCMR g Ic were significantly (p < 0.02) lower in the AD group in frontal, temporal, and entire cortex. Because many PET studies use assumed values for rate constants derived from normal subjects to calculate rCMR g Ic, we chose to investigate the ef fects of using averaged values for rate constants from inappropriate subjects in the calculation of J Cereb Blood Flow Metab, Vol. 11, No.2, 1991 rCMR g Ic. This was accomplished by utilizing the operational equation as modified by Phelps et al. (1979) to calculate the "correct" rCMR g Ic using the averaged rate constants from the entire cortical re gion of the appropriate population. This "correct" value was then compared with an "incorrect" value obtained using averaged rate constants from the in appropriate population, that is, AD rate constants in the control subjects and vice versa. In the tem poral cortex, we found that use of the control rate constants with the AD subjects' PET and input function data resulted in an underestimation of rCMR g Ic that averaged 10.7% (SD 5.1, range 4.5-17.6%) when compared with the use of the averaged AD subjects' rate constants. In the control subjects, use of the AD rate constants with the control PET Values are means for the group (n = 6 for AD, n = 7 for controls), with SEM in parentheses. " AD mean significantly different from control mean, p < 0.05. b AD mean significantly different from control mean, p < 0.02. and input function data overestimated rCMRglc by an average of 6.1% (SD 2.0, range 3.9-9.0%). Sim ilar results were found for the entire cortical region.
DISCUSSION
The rate constant K J * reflects FDG transport across the blood-brain barrier and through the in terstitial space into the cell. We found a statistically significant reduction in KJ *, of �20%, in the frontal and temporal cortex of patients with AD relative to age-matched controls. Differences in K J * between AD patients and controls were minimal in occipital cortex and white matter, regions that are thought to be relatively spared by Alzheimer neuropathology (Brun and Englund, 1981; McGeer et al., 1986) . These results can be interpreted as evidence for an abnormality of glucose transport in AD. These data cannot determine whether this abnormality resides at the blood-brain barrier or between the barrier and the neuron, but it is more likely the former in view of the much larger surface area of neuronal membranes, which does not inhibit glucose trans port (Pardridge, 1983) .
Previous work from our laboratory also estimated the rate constants for glucose transport and phos phorylation and found no statistically significant differences for the values of K J *, k2 *, and k3 * be tween AD and control subjects (Friedland et al., 1989) . However, similar trends appeared in those data, as values for KJ* and k3* were lower in AD patients than controls in affected brain regions. Al though the different results may be explained by the different patient groups studied, the improved res olution of 2.6-mm FWHM in-plane and 6 mm axi ally of the PET 600 tomograph used in this experi ment (Derenzo et al., 1988) compared with the 8mm FWHM in-plane and 10-mm axial resolution of the Donner 280 crystal tomograph (PET 280) used in the previous study (Derenzo et aI., 1981 ) allowed more precise sampling of gray matter radioactivity concentrations and may account in part for the dif ferent results. Since differences in glucose utiliza tion between AD and control patients have been found to be greater in gray matter than white matter structures, minimization of the contribution of white matter measurements will have the effect of accentuating differences between the two groups.
In addition to differences in instrument resolu tion, this study employed a different method of measuring the input function. The use of actual ra dial arterial sampling with on-line activity measure ment, as opposed to sampling of "arterialized" ve nous blood, allowed characterization of the "true" arterial input. Accurate knowledge of the shape of the input function is particularly important in dy namic PET data analysis, and use of a venous or undersampled input function will bias the results of the fitting procedure.
Values of the rate constants and metabolic rates found by us in both subject groups are considerably higher than those reported by other investigators who also estimated these parameters (Phelps et aI., 1979; Heiss et aI., 1984; Reivich et aI., 1985; Evans et aI., 1986; Sasaki et aI., 1986) . These differences may result from the ages and medical conditions of patients studied as well as the activation states of the patients during the PET study. Our patients were screened to ensure good general medical health and were studied without sensory depriva tion. Technical differences are also likely to ac count for the discrepancies, in particular, the effects of increased instrument resolution on mea sured metabolic rates. Grady et al. (1989) , compar ing tomographs with transverse resolutions of 17 and 6 mm, noted that gray matter metabolic rate values obtained with the higher-resolution instru ment were 30-120% greater. Similar increases are seen when comparing the present metabolic rate values with those obtained using the PET 280 (Friedland et aI., 1989) . In addition to the higher spatial resolution of our scanner, other technical factors that differ between our study and those per formed in other laboratories are the high temporal resolution of PET and input function data sampling, our use of whole-blood rather than plasma radioac tivity in the input function, and the inclusion of Iv and to in the fit. The use of measured as opposed to calculated attenuation and drawing of ROIs in small cortical regions with highest tracer uptake will also result in higher metabolic rate values (lagust et aI., 1986) . All of these factors taken together provide the likely explanation for the higher values of the metabolic rates and kinetic parameters reported here.
The variability of the data is similar to that re ported in previous studies, with coefficients of vari ation in the range of 15-20% for K] * and larger co efficients of variation for k2 *, k3 *, and Iv. Similar patterns of the uncertainties of the parameter esti mates were also seen, with smaller uncertainties for K] * and larger uncertainties for the other parame ters. This suggests that a major source of the vari ability of the data between subjects is the uncer tainty of the estimates themselves. These uncertain ties depend upon the sensitivity of the tomograph, the ROI size, and the amount of tracer uptake in a given region. The relatively larger variability of k3 * probably accounts for our failure to detect signifi cant differences in this variable between the two groups.
The differences that we found in the rate con stants will affect the values of rCMRglc that are cal culated with the operational equation when as-J Cereb Blood Flow Metab, Vol. ll, No.2, 1991 sumed values of the rate constants are used. Un derestimation of AD metabolic rates that result from the use of normal values of the rate constants in AD patients may exaggerate differences between AD and control groups. The importance of this un derestimation for data analysis depends upon the size of group differences in metabolic rates and the between-subject variability, but it may introduce an additional methodologic variable when comparing results from different laboratories.
Interpretation of the differences in rate constants is complicated by the fact that the estimates of many of the parameters are highly correlated. For example, k2 * and k3 * are positively correlated and consequently Vd and k3 * are negatively correlated. There are also very strong correlations between Kl * and k2 *. Reductions in rCMRglc can be accounted for by a decrease either in Vd or in k3 *. In this study we have detected both a decline in Vd, which could be consequent to reductions in K] * or increases in k2 *, as well as a reduction in k3 * in the AD group. The actual decline in metabolic rates could thus be related to changes in any or all of the three rate constants. While the changes in K 1 * are statistically significant, the role of changes in k/ may be of considerable biological importance, as discussed below. It is uncertain whether the increase in k2 * is of biological significance or whether it represents an artifact of the uncertainty of the estimates and the correlation of this variable with the other rate con stants.
Although the differences in K] * between AD and control subjects could be explained by differences in capillary density, our findings are also in keeping with recent in vitro studies of glucose transport in AD. Kalaria and Harik (1989) utilized [ 3 H]cytocha lasin B to quantitate the hexose transporter in iso lated AD brain microvessels and whole samples of cerebral gray matter. They found 50% reductions of cytochalasin B binding in AD patients relative to controls in microvessels, as well as in frontal and temporal cortex and hippocampus. The putamen and cerebellum were unaffected. They suggested that these results could explain in part the reduced glucose metabolism observed in PET studies. Our PET results support these findings, since the activ ity of the hexose transporter is reflected in the value of K 1 *. The discrepancy in magnitude between our results and theirs may reflect the differences be tween in vitro and in vivo measurements. Reduction in K 1 *, however, is unlikely to be the cause of reduced glucose metabolism in AD. Al though metabolic rate is proportional to V dk3 * and the decrease in Kl * that we detected will decrease V d' the magnitude of the changes in K 1 * alone is not sufficient to account for the change in rCMR glc. While K\ * decreases in frontal and temporal cortex were in the range of 20%, rCMRglc declined by �36% in these same regions, indicating that other factors besides K \ * changes must be responsible for the diminished glucose metabolism. In addition, for physiological reasons it is unlikely that changes in glucose transport would account for large metabolic changes. Glucose transport is not the rate-limiting step in metabolism, and concentrations of brain glu cose are usually orders of magnitude greater than the Km for the rate-limiting hexokinase enzyme, which is approximately 40 f.LM (Lund-Anderson, 1979) . It is possible to estimate regional brain glu cose concentration (CE), since it is proportional to the product Cp Yd' Because the apparent volumes of distribution of FDG and glucose differ, a correction term (A) is employed to describe the ratio between the respective volumes of distribution. A recent measurement of the volume of distribution of glu cose by Mori et al. (1989) found a value of 0.24 ± 0.01 ml/g. Assuming that our measured value of 0.62 is a correct estimate of the normal apparent volume of distribution of FDG (it is taken from the entire cortex of control subjects), this gives a value for A of 2.6 ml/g, which is similar to the value of 2.29 for the e 4 C]deoxyglucose/glucose A (Mori et al., 1989) in normoglycemic rats. With a value of 2.6 ml/g for A, calculated brain concentrations of glu cose average 1.2 f.Lmol/g (SD 0.04, range 0.6-1.7 f.Lmol/g) in temporal cortex and 1.3 f.Lmol/g (SO 0.03, range 1.0-1.7 f.1mol/g) in frontal cortex in the AD patients, which exceeds the Km of hexokinase by >10-fold. Of interest, Gjedde et al. (1985) used 3-O-[ II C]methyl-D-glucose to estimate glucose con tent in brain tissue in humans and found an average value of 1.3 f.1mol l g.
Because changes in glucose transport cannot en tirely account for the changes in glucose metabo lism seen in AD, other factors must also be in volved. The rate constant for glucose phosphoryla tion (k3) is defined by the Michaelis-Menten constants for hexokinase as k3 = V max/( Km + CE). Because glucose transport is impaired, with a con sequent reduction of C E' an increase in k3 * for FDG would be expected. Since we did not detect such an increase, and in fact noted large (although statisti cally insignificant) decreases, it stands to reason that either V max must decrease or Km must increase. Because Km shows little variation across species, and because regulation of hexokinase V max is a physiologic mechanism for the regulation of glucose metabolism (Lund-Anderson, 1979) , decreases in the V max of hexokinase in AD may play a patho physiologic role in reductions of glucose metabo-lism in the disease. Although cerebral atrophy should not affect k3 * , nonuniform tissue loss, affect ing metabolic tissue out of proportion to tissue re sponsible for glucose transport, will decrease k3 * . The widespread neuronal loss that has been re ported in AD (Terry et al., 1981) would be expected to diminish the concentration of hexokinase in brain tissue, thus leading to a decrease in V max (which is concentration dependent) and hence k3 * . Indeed, previous work from our laboratory (Friedland et al., 1989) and elsewhere (Marcus et aI., 1989) supports the contention that k3 * may be diminished in AD.
These results provide supportive in vivo evidence for an abnormality of glucose transport in the brains of patients with AD. However, this abnormality does not appear to be responsible for the reduction of cerebral glucose metabolism found in the dis ease, since the magnitude of the transport changes is insufficient to alter intracellular glucose content enough to reduce cerebral glucose metabolism. While the cause of the reduction in glucose metab olism seen in AD remains uncertain, our data sug gest an alteration in the Michaelis-Menten con stants for hexokinase.
